NZ257059A - 1-(indol-5-yl)imidazopyridine and -benzimidazole derivatives - Google Patents

1-(indol-5-yl)imidazopyridine and -benzimidazole derivatives

Info

Publication number
NZ257059A
NZ257059A NZ257059A NZ25705993A NZ257059A NZ 257059 A NZ257059 A NZ 257059A NZ 257059 A NZ257059 A NZ 257059A NZ 25705993 A NZ25705993 A NZ 25705993A NZ 257059 A NZ257059 A NZ 257059A
Authority
NZ
New Zealand
Prior art keywords
alkyl
indol
aryl
ylmethyl
benzimidazole
Prior art date
Application number
NZ257059A
Other languages
English (en)
Inventor
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ257059A publication Critical patent/NZ257059A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
NZ257059A 1992-11-02 1993-10-19 1-(indol-5-yl)imidazopyridine and -benzimidazole derivatives NZ257059A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02

Publications (1)

Publication Number Publication Date
NZ257059A true NZ257059A (en) 1997-07-27

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ257059A NZ257059A (en) 1992-11-02 1993-10-19 1-(indol-5-yl)imidazopyridine and -benzimidazole derivatives

Country Status (27)

Country Link
US (1) US5886008A (cg-RX-API-DMAC7.html)
EP (2) EP1094064A1 (cg-RX-API-DMAC7.html)
JP (1) JP2788551B2 (cg-RX-API-DMAC7.html)
KR (1) KR0163371B1 (cg-RX-API-DMAC7.html)
CN (1) CN1051313C (cg-RX-API-DMAC7.html)
AT (1) ATE202102T1 (cg-RX-API-DMAC7.html)
AU (1) AU685066B2 (cg-RX-API-DMAC7.html)
BR (1) BR9307348A (cg-RX-API-DMAC7.html)
CA (2) CA2340999C (cg-RX-API-DMAC7.html)
CZ (1) CZ283001B6 (cg-RX-API-DMAC7.html)
DE (1) DE69330351T2 (cg-RX-API-DMAC7.html)
DK (1) DK0666858T3 (cg-RX-API-DMAC7.html)
EG (1) EG20396A (cg-RX-API-DMAC7.html)
ES (1) ES2157224T3 (cg-RX-API-DMAC7.html)
FI (2) FI111257B (cg-RX-API-DMAC7.html)
GR (1) GR3036579T3 (cg-RX-API-DMAC7.html)
HU (1) HU222235B1 (cg-RX-API-DMAC7.html)
IL (1) IL107386A (cg-RX-API-DMAC7.html)
MY (1) MY109696A (cg-RX-API-DMAC7.html)
NO (1) NO309652B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ257059A (cg-RX-API-DMAC7.html)
PL (1) PL176091B1 (cg-RX-API-DMAC7.html)
PT (1) PT666858E (cg-RX-API-DMAC7.html)
RU (1) RU2134266C1 (cg-RX-API-DMAC7.html)
TW (1) TW251284B (cg-RX-API-DMAC7.html)
WO (1) WO1994010171A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA938137B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
WO1995006636A1 (en) * 1993-08-31 1995-03-09 Pfizer Inc. 5-arylindole derivatives
JP2829788B2 (ja) * 1994-02-10 1998-12-02 ファイザー インク. ベンゾジアゼピン受容体部位アゴニスト及びアンタゴニストとしての5−ヘテロアリールインドール誘導体
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
JPH11502816A (ja) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー 5−置換−3−(1,2,3,6−テトラヒドロピリジン−4−イル)−および3−(ピペリジン−4−イル)−1h−インドール類:新規5−ht▲下1f▼アゴニスト
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー N−[2−置換−3−(2−アミノエチル)−1h−インドール−5−イル]−アミド:新規5−ht▲下1f▼作動剤
EE04280B1 (et) 1997-07-03 2004-04-15 Dupont Pharmaceuticals Company Imidasopürimidiinid ja imidasopüridiinid neuroloogiliste häirete käitlemiseks
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
JP2002519321A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー セロトニン関連系に効果を有するピロリジン、及び、ピロリン誘導体
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
EP1658289B1 (en) * 2003-08-21 2009-03-18 OSI Pharmaceuticals, Inc. 3-substituted imidazopyridine-derivatives as c-kit inhibitors
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
SG148201A1 (en) 2003-11-25 2008-12-31 3M Innovative Properties Co Substituted imidazo ring systems and methods
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
UY36654A (es) * 2015-04-29 2016-10-31 Janssen Pharmaceutica Nv Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
CN107567452B (zh) 2015-04-29 2020-07-07 詹森药业有限公司 咪唑并哌嗪和吡唑并嘧啶以及它们作为ampa受体调节剂的用途
BR112017023200A2 (pt) 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
US10611730B2 (en) 2015-04-29 2020-04-07 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
EP3371170B1 (en) 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
RO111767B1 (ro) * 1990-10-15 1997-01-30 Pfizer Derivati de indol, procedee si intermediari pentru prepararea acestora, compozitii farmaceutice si metoda pentru tratarea unor afectiuni
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
BR9307348A (pt) 1999-05-11
JP2788551B2 (ja) 1998-08-20
IL107386A0 (en) 1994-01-25
TW251284B (cg-RX-API-DMAC7.html) 1995-07-11
ZA938137B (en) 1995-05-02
ATE202102T1 (de) 2001-06-15
PL176091B1 (pl) 1999-04-30
GR3036579T3 (en) 2001-12-31
PT666858E (pt) 2001-09-28
IL107386A (en) 1999-03-12
FI111257B (fi) 2003-06-30
NO309652B1 (no) 2001-03-05
EP0666858A1 (en) 1995-08-16
FI934825A0 (fi) 1993-11-01
CA2148380A1 (en) 1994-05-11
RU2134266C1 (ru) 1999-08-10
JPH07508759A (ja) 1995-09-28
KR0163371B1 (ko) 1998-12-01
NO951633D0 (no) 1995-04-28
FI20002505A7 (fi) 2000-11-15
HU222235B1 (hu) 2003-05-28
PL308669A1 (en) 1995-08-21
HUT66011A (en) 1994-08-29
DK0666858T3 (da) 2001-08-27
EP0666858B1 (en) 2001-06-13
ES2157224T3 (es) 2001-08-16
CA2340999C (en) 2005-01-04
FI20002505L (fi) 2000-11-15
EG20396A (en) 1999-02-28
CN1094727A (zh) 1994-11-09
CA2148380C (en) 2001-08-14
WO1994010171A1 (en) 1994-05-11
AU5329494A (en) 1994-05-24
CN1051313C (zh) 2000-04-12
CA2340999A1 (en) 1994-05-11
EP1094064A1 (en) 2001-04-25
CZ283001B6 (cs) 1997-12-17
MY109696A (en) 1997-04-30
DE69330351D1 (de) 2001-07-19
NO951633L (no) 1995-04-28
FI934825L (fi) 1994-05-03
RU95109927A (ru) 1997-01-10
KR950704313A (ko) 1995-11-17
CZ110895A3 (en) 1995-11-15
DE69330351T2 (de) 2001-09-20
US5886008A (en) 1999-03-23
AU685066B2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
EP0666858B1 (en) 5-arylindole derivatives and their use as serotonin (5-ht 1) agonists
AU671959B2 (en) Indole derivatives
EP0716649B1 (en) 5-arylindole derivatives
FI92067B (fi) Menetelmä valmistaa terapeuttisesti aktiivisia mono- tai disubstituoituja (imidatsol-4-yyli)metyylipyrido/4,3-b/indol- ja atsepino/4,3-b/indol-1-oneja
EP0629199B1 (en) Indole derivatives as 5-ht1 agonists
JPH07506825A (ja) 5−ht1レセプターアゴニストとしての縮合イミダゾール及びトリアゾール誘導体
PL210413B1 (pl) Pochodne indoliloalkiloaminy
NZ228721A (en) Substituted indoles and indazoles and pharmaceutical compositions